Skip to textbook content
Doctor’s PassportTextbook
QuestionsFlashcardsBriefsDashboardAccount
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Benzodiazepine and gabapentinoid dependence

Psychiatry · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Seizure, delirium or respiratory depression needs urgent care

Abrupt benzodiazepine cessation can cause seizures, delirium and psychosis, while high-dose gabapentinoid withdrawal can also cause seizures; intoxication becomes especially dangerous when either drug is combined with opioids, alcohol or other sedatives.

Action: For reduced consciousness or slow breathing, call emergency services, support airway and ventilation, and give naloxone if opioid exposure is possible. For a withdrawal seizure, delirium, severe agitation or psychosis, transfer to acute care, restore a safe clinician-directed regimen where appropriate, treat complications and identify all recently reduced substances and medical causes.

Synopsis

Recognise expected physical dependence and problematic use without blame, prevent overdose and abrupt-withdrawal emergencies, and construct individualized, slow, flexible benzodiazepine or gabapentinoid reduction plans that continue treatment of the underlying condition.

  • Physical dependence is an expected neuroadaptation and does not by itself mean addiction; addiction adds impaired control, prioritisation, craving or continued use despite harm.
  • The MHRA strengthened warnings in 2026 across gabapentinoids, benzodiazepines and Z-drugs for addiction, dependence, withdrawal and tolerance.
  • Do not stop a benzodiazepine or gabapentinoid abruptly except in exceptional serious medical circumstances; assess seizure risk, co-dependence and the original indication first.
  • For benzodiazepines, NICE suggests a slow stepwise reduction proportionate to the current dose, with smaller decrements as the dose becomes lower; a short-half-life drug may be switched to a longer-half-life option.
  • For gabapentinoids, NICE advises a fixed amount at each decrement, adjusted to the person rather than a fixed percentage schedule.
  • A current pregabalin SmPC gives illustrative minimum discontinuation periods of at least 1 week from 150–300 mg daily and at least 3 weeks from 600 mg daily, but longer individualized tapers are often needed after long-term use.
  • If new or intolerable symptoms follow a reduction, pause, make the next decrement smaller or return to the previous tolerated dose while reassessing withdrawal versus recurrence of the original condition.
  • Do not treat withdrawal by adding another dependence-forming medicine; continue non-drug care for anxiety, insomnia or pain and consider group CBT during benzodiazepine withdrawal.

    • Key red flags

    A seizure, fluctuating confusion, hallucinations, marked agitation or severe autonomic symptoms after abrupt dose reduction requires urgent hospital assessment.

    Drowsiness, slurred speech, ataxia, cyanosis or slow breathing suggests sedative toxicity, particularly with opioids, alcohol or several prescribed depressants.

    Escalating dose, early refill requests, multiple prescribers, lost prescriptions, internet supply or using medication for intoxication indicates problematic use requiring coordinated review.

    Pregnancy or planned pregnancy, epilepsy, severe respiratory disease, renal impairment, frailty or unstable mental illness materially changes withdrawal planning.

    Suicidal intent, severe self-neglect, exploitation, unsafe storage around children or diversion under coercion requires immediate safety and safeguarding action.

    Investigation priorities

    01
    Verified medication reconciliationFirst step

    Establish exact drug, formulation, prescribed dose, actual use, duration, prescribers and recent supply.

    Management branches

    Initial reviewSeparate benefit, dependence and harm

    A person is taking a benzodiazepine or gabapentinoid long term, at high dose or with concerning symptoms.

    1. Reconcile all medicines and substances, assess the original indication, current benefit, adverse effects, dependence and impaired control.
    2. Check respiratory, seizure, mental-health, pregnancy, renal, hepatic and safeguarding risks before choosing an outpatient plan.
    3. Explain dependence and withdrawal without blame, share written information and agree the first realistic goal.

    Key medicines

    Individualized benzodiazepine taperReduce slowly in steps proportionate to the current daily dose, making each decrement smaller as the dose falls; agree the interval and percentage with the person and modify it after review. When withdrawing a short-half-life benzodiazepine, consider a clinician-supervised conversion to a longer-half-life benzodiazepine before reduction.There is no reliable universal diazepam-equivalent schedule. High dose, long duration, prior seizures, pregnancy, liver disease, multiple sedatives and illicit supply require specialist input; never switch or taper mechanically, and do not stop abruptly except for exceptional serious toxicity.
    Pregabalin discontinuationReduce by a fixed milligram amount at each decrement, individualized to dose, duration and symptoms. A current pregabalin SmPC gives examples of at least 1 week to discontinue 150–300 mg daily and at least 3 weeks from 600 mg daily; pause or return to the previous tolerated dose if withdrawal reactions occur.Long-term or high-dose use may need much longer than these minimum product examples. Adjust for renal function, epilepsy, pregnancy and co-prescribed opioids or sedatives; convulsions, including status epilepticus, are reported during use or shortly after discontinuation.
    Open full textbook →Answer 2 questions
    Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
    Sources

    Sources and review status

    National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

    • NICE NG215 dependence and withdrawal recommendationsShared decisions, slow tapering, drug-specific decrement pattern and withdrawal response.
    • MHRA improved gabapentinoid benzodiazepine and Z-drug informationJanuary 2026 strengthened addiction, dependence, tolerance and withdrawal warnings.
    • Pregabalin Lyrica 75 mg capsule SmPCCurrent discontinuation examples, seizure, respiratory, renal and pregnancy cautions.
    • DHSC drug misuse and dependence UK clinical guidelinesOrange Book prescribed-medicine dependence and polydrug safety.

    Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

    Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom